ATE342053T1 - Formulierungen zur inhalation - Google Patents

Formulierungen zur inhalation

Info

Publication number
ATE342053T1
ATE342053T1 AT03737353T AT03737353T ATE342053T1 AT E342053 T1 ATE342053 T1 AT E342053T1 AT 03737353 T AT03737353 T AT 03737353T AT 03737353 T AT03737353 T AT 03737353T AT E342053 T1 ATE342053 T1 AT E342053T1
Authority
AT
Austria
Prior art keywords
inhalation formulations
solvate
compound
formula
formulation
Prior art date
Application number
AT03737353T
Other languages
English (en)
Inventor
Keith Biggadike
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27732221&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE342053(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE342053T1 publication Critical patent/ATE342053T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
AT03737353T 2002-02-04 2003-02-04 Formulierungen zur inhalation ATE342053T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/066,964 US6750210B2 (en) 2000-08-05 2002-02-04 Formulation containing novel anti-inflammatory androstane derivative

Publications (1)

Publication Number Publication Date
ATE342053T1 true ATE342053T1 (de) 2006-11-15

Family

ID=27732221

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03737353T ATE342053T1 (de) 2002-02-04 2003-02-04 Formulierungen zur inhalation

Country Status (8)

Country Link
US (2) US6750210B2 (de)
EP (1) EP1471896B1 (de)
JP (1) JP2005519925A (de)
AT (1) ATE342053T1 (de)
AU (1) AU2003244450A1 (de)
DE (1) DE60308997T2 (de)
ES (1) ES2274247T3 (de)
WO (1) WO2003066032A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
AU2001275760B2 (en) 2000-08-05 2005-03-17 Glaxo Group Limited 6.alpha., 9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid S-fluoromethyl ester as an anti-inflammatory agent
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
HUP0400070A2 (hu) * 2001-04-30 2004-04-28 Glaxo Group Limited 17alfa-helyzetben ciklusos észtercsoportot tartalmazó androsztán-17béta-karbotiosav-észter-származékok mint gyulladásgátló szerek, eljárás a vegyületek előállítására és ezeket tartalmazó gyógyszerkészítmények
JP2005500290A (ja) * 2001-06-12 2005-01-06 グラクソ　グループ　リミテッド 抗炎症性の、１７β−カルボチオアートアンドロスタン誘導体である１７α複素環エステル
US20030105162A1 (en) * 2001-08-21 2003-06-05 Celluar Sciences, Inc. Method for treating bronchial constriction and bronchospasm
GB0125259D0 (en) * 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
ATE453421T1 (de) * 2002-05-09 2010-01-15 Glaxo Group Ltd Flüssigkeit abgebende vorrichtung
GB0217798D0 (en) * 2002-08-01 2002-09-11 Glaxo Group Ltd A fluid dispensing device
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0311701D0 (en) * 2003-05-21 2003-06-25 Karib Kemi Pharm Liited Improved metered dose inhaler product
AU2004287261B8 (en) 2003-11-03 2011-01-27 Glaxo Group Limited A fluid dispensing device
GB0405477D0 (en) * 2004-03-11 2004-04-21 Glaxo Group Ltd A fluid dispensing device
EP1699847B1 (de) * 2003-12-30 2011-04-13 3M Innovative Properties Company Herstellungsverfahren von medizinischen zusammensetzungen
AU2005290068A1 (en) * 2004-09-24 2006-04-06 3M Innovative Properties Company Medicinal aerosol formulations and methods of synthesizing ingredients therefor
EP1824543B1 (de) * 2004-12-15 2013-01-23 3M Innovative Properties Company Elastomere dichtungen zur verwendung in medizinischen aerosolvorrichtungen
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
GB0507224D0 (en) * 2005-04-09 2005-05-18 Glaxo Group Ltd A fluid dispensing device
GB0604319D0 (en) * 2006-03-03 2006-04-12 Optinose As Nasal delivery
MX2008011967A (es) * 2006-03-22 2009-01-14 Glaxo Group Ltd Formulaciones novedosas.
CA2657681C (en) 2006-07-14 2019-03-19 Ac Immune S.A. Humanized antibodies against beta amyloid protein
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
TWI557136B (zh) * 2007-06-12 2016-11-11 Ａｃ免疫公司 特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途
EP2238166B1 (de) * 2007-10-05 2013-11-27 Genentech, Inc. Verwendung eines anti-amyloid-beta-antikörpers bei augenkrankheiten
NZ601858A (en) * 2007-10-05 2014-03-28 Genentech Inc Methods and compositions for diagnosis and treatment of amyloidosis
MY158339A (en) 2009-04-23 2016-09-30 Theravance Respiratory Co Llc DIAMIDE COMPOUNDS HAVING MUSCARING RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
WO2012009609A1 (en) 2010-07-15 2012-01-19 Battelle Memorial Institute Biobased polyols for potential use as flame retardants in polyurethane and polyester applications
EP2598882B1 (de) 2010-07-30 2017-07-26 AC Immune S.A. Sichere und funktionelle humanisierte antikörper für die verwendung in der behandlung von einer amyloidose
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
MX368835B (es) * 2013-12-30 2019-10-18 Chiesi Farm Spa Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol.
HUE039359T2 (hu) * 2013-12-30 2018-12-28 Chiesi Farm Spa Glikopirrónium-bromid és formoterol kombináció stabil, túlnyomásos aeroszol oldat készítménye

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR580494A (fr) 1923-07-10 1924-11-07 Const Metalliques Schiltigheim Procédé d'établissement des buses d'aération ou autres tuyaux
US3067197A (en) * 1961-04-26 1962-12-04 Pfizer & Co C 11-oxygenated 6alpha-fluoro-16-methylene-delta-pregnenes and derivatives
US3639434A (en) * 1967-02-02 1972-02-01 Boots Pure Drug Co Ltd 17-acyloxysteroids and their manufacture
GB1384372A (en) 1971-01-20 1975-02-19 Glaxo Lab Ltd Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids
US3828080A (en) * 1972-01-20 1974-08-06 Glaxo Lab Ltd Androstane-17beta-carboxylic acids and processes for the preparation thereof
US3989686A (en) * 1972-06-15 1976-11-02 Glaxo Laboratories Limited Anaesthetic steroids of the androstane series and process for preparing same
GB1438940A (en) * 1972-07-19 1976-06-09 Glaxo Lab Ltd 17beta-haloalkoxycarbonyl-17alpha-oxysteroids
DE2336693A1 (de) 1973-07-19 1975-02-06 Nassheuer Ind Ofenbau Jean Strahlheizrohr
GB1517278A (en) * 1974-08-30 1978-07-12 Glaxo Lab Ltd Alkyl and haloalkyl androsta-1,4,15-triene and-4,15-diene-17beta-carboxylates
US4093721A (en) * 1974-08-30 1978-06-06 Glaxo Laboratories Limited Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
DE2538569A1 (de) 1975-08-29 1977-03-03 Siemens Ag Verfahren zur metallisierung von duroplasten
CH628355A5 (de) * 1976-02-24 1982-02-26 Ciba Geigy Ag Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze.
US4187301A (en) * 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
US4188385A (en) * 1978-04-05 1980-02-12 Syntex (U.S.A.) Inc. Thioetianic acid derivatives
US4261984A (en) * 1978-04-05 1981-04-14 Syntex (U.S.A.) Inc. 17β-thiocarboxylic acid esters of 3-oxo-4-halo-16β-methylandrost-4-enes
US4263289A (en) * 1978-04-05 1981-04-21 Syntex (U.S.A.) Inc. Thio etianic acid derivatives
US4198403A (en) 1978-04-05 1980-04-15 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes
DE2817988A1 (de) * 1978-04-25 1979-11-08 Hoechst Ag Corticoid 17-alkylcarbonate und verfahren zu deren herstellung
US4310466A (en) * 1979-08-31 1982-01-12 Syntex (U.S.A.) Inc. Thio etianic acid derivatives
US4267173A (en) * 1979-11-05 1981-05-12 Schering Corporation Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor
BE887518A (fr) 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates d'androstanes
US4710495A (en) * 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US4996335A (en) * 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
SE449106B (sv) 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4607028A (en) * 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters
EP0179583A1 (de) 1984-10-04 1986-04-30 Merck & Co. Inc. System zur Verbesserung der Auflösungsgeschwindigkeit in Wasser und der Löslichkeit von schwer löslichen Arzneimitteln
US4861765A (en) * 1985-06-26 1989-08-29 Jouveinal 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them
ZA872389B (en) 1987-04-02 1987-11-25 Advanced Polymer Systems Inc Composition and method for delivering a steroid active ingredient
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
JP3087763B2 (ja) 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
GB9103764D0 (en) 1991-02-22 1991-04-10 Glaxo Group Ltd Compositions
US5250293A (en) * 1991-04-22 1993-10-05 Gleich Gerald J Method for the treatment of hypersensitivity diseases by administration of anionic polymers
TW247878B (de) 1991-07-02 1995-05-21 Takeda Pharm Industry Co Ltd
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
ES2122261T3 (es) 1993-03-17 1998-12-16 Minnesota Mining & Mfg Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester.
DE4328819A1 (de) 1993-08-27 1995-03-02 Hoechst Ag Corticosteroid-17-alkylcarbonat-21/0/-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE4333920A1 (de) 1993-10-05 1995-04-13 Hoechst Ag Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US5420120A (en) * 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
IL109656A (en) 1994-05-15 1998-02-22 Chemagis Ltd Process for the manufacture of androstane - 17 - carbothioates and androstane - 17 - carbothioates prepared thereby
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
GB9419536D0 (en) * 1994-09-28 1994-11-16 Glaxo Inc Medicaments
SA95160463B1 (ar) 1994-12-22 2005-10-04 استرا أكتيبولاج مساحيق للاستنشاق
DE19528145A1 (de) 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
GB9521696D0 (en) 1995-10-23 1996-01-03 Bayer Ag Combination of LTD4 receptor antagonists with glucocorticosteriods
US5707984A (en) * 1995-12-08 1998-01-13 G. D. Searle & Co. Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs
PT876392E (pt) 1995-12-29 2000-12-29 Glaxo Group Ltd Derivados de lactona de derivados 17beta-carboxi carbotio e amida androstano
US5981517A (en) * 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
EP0954318A1 (de) 1996-06-04 1999-11-10 The Procter & Gamble Company Nasenspray enthaltend ein intranasales steroid und ein antihistamin
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
ATE530180T1 (de) 1997-04-02 2011-11-15 Brigham & Womens Hospital Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen
EP0998484B1 (de) 1997-06-30 2004-03-03 Glaxo Group Limited Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
SE9704833D0 (sv) 1997-12-22 1997-12-22 Astra Ab New formulation
US5972920A (en) * 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
US6136294C1 (en) 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
US6261539B1 (en) 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
GB9828721D0 (en) 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
AU3411000A (en) 1999-03-24 2000-10-09 Glenayre Electronics, Inc Computation and quantization of voiced excitation pulse shapes in linear predictive coding of speech
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
WO2001015744A1 (en) 1999-08-31 2001-03-08 The Brigham And Women's Hospital, Inc. Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
ATE363074T1 (de) 1999-09-14 2007-06-15 Xenoport Inc Substrate und screeningverfahren für transportproteine
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
US20020133032A1 (en) 2000-02-25 2002-09-19 Jufang Barkalow Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009591D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
GB0016040D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0017988D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Novel process
CA2412376A1 (en) 2000-07-26 2002-01-31 Onkar N. Singh Pharmaceutical suspension compositions lacking a polymeric suspending agent
AU2001275760B2 (en) 2000-08-05 2005-03-17 Glaxo Group Limited 6.alpha., 9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid S-fluoromethyl ester as an anti-inflammatory agent
AR032362A1 (es) 2000-08-14 2003-11-05 Glaxo Group Ltd Formulacion topica estable de una emulsion de aceite en agua y proceso para su preparacion
AU2001290146A1 (en) 2000-09-29 2002-04-08 Glaxo Group Limited Compounds useful in the treatment of inflammatory diseases
US20020132803A1 (en) 2001-01-05 2002-09-19 Mahendra Dedhiya Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
EP1366025B1 (de) 2001-03-08 2007-06-27 Glaxo Group Limited Agonisten von beta-adrenorezeptoren
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent

Also Published As

Publication number Publication date
AU2003244450A1 (en) 2003-09-02
DE60308997D1 (de) 2006-11-23
US6750210B2 (en) 2004-06-15
JP2005519925A (ja) 2005-07-07
US20050130947A1 (en) 2005-06-16
DE60308997T2 (de) 2007-08-30
EP1471896B1 (de) 2006-10-11
US20020173496A1 (en) 2002-11-21
WO2003066032A1 (en) 2003-08-14
EP1471896A1 (de) 2004-11-03
ES2274247T3 (es) 2007-05-16

Similar Documents

Publication Publication Date Title
ATE342053T1 (de) Formulierungen zur inhalation
ATE291898T1 (de) Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
DE60031504D1 (de) Fluticasonpropionat arzneizubereitung
IT1317846B1 (it) Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0016876D0 (en) Novel formulation
MXPA03000442A (es) Una formulacion medicinal en aerosol.
WO2004000290A8 (en) Pharmaceutical composition
MXPA03010761A (es) Combinaciones farmaceuticas.
GB0109122D0 (en) Novel compounds
BRPI0415053B8 (pt) inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
WO2001076601A3 (en) Pharmaceutical compositions comprising salmeterol and ipratropium
DE60311665D1 (de) Pharmazeutische zusammensetzungen
ITBO20020310A0 (it) Apparato di controllo dell ' erogazione di gas medicinali , particolarmente per l ' ausilio alla respirazione
AU1534501A (en) Pharmaceutical formulations of salmeterol
IL169356A0 (en) Controlled dosage aerosols with lecithin as surface-active agent

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties